Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 283

Sort by

Sort Order Select

Journal Articles

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O’Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating

Blood (2023) 142 (21): 1784–1788.

https://doi.org/10.1182/blood.2023020158

Published: 2023

Includes: Supplemental data

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Blood (2022) 140 (Supplement 1): 234–237.

https://doi.org/10.1182/blood-2022-170850

Published: 2022

Journal Articles

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Sai Prasad Desikan, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Maro Ohanian, Naveen Pemmaraju, Courtney D. DiNardo, Marina Konopleva, Tapan M. Kadia, Susan O'Brien, Zeev E. Estrov, Deborah A Thomas, Jan A. Burger, Philip A. Thompson, William G. Wierda

Blood (2022) 140 (Supplement 1): 9876–9878.

https://doi.org/10.1182/blood-2022-167284

Published: 2022

Journal Articles

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, Jon A Hernandez, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, William G. Wierda

Blood (2022) 140 (Supplement 1): 238–240.

https://doi.org/10.1182/blood-2022-170030

Published: 2022

Journal Articles

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Tareq Abuasab, Fadi Haddad, Shehab Fareed Mohamed, Jeffrey L. Jorgensen, Sa A Wang, Philip A. Thompson, Tapan M. Kadia, Yesid Alvarado, Sherry A. Pierce, Michael J. Keating, David McCue, Hagop Kantarjian, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 9385–9386.

https://doi.org/10.1182/blood-2022-165639

Published: 2022

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2021) 138 (Supplement 1): 2626.

https://doi.org/10.1182/blood-2021-154195

Published: 2021

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Blood (2021) 138 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2021-154454

Published: 2021

Journal Articles

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

Philip A. Thompson, Yan Wang, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Chongjuan Wei, Ana Ayala, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, William G. Wierda

Blood (2021) 138 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2021-149919

Published: 2021

Journal Articles

Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab

Mariela Sivina, Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson, Zeev E. Estrov, Hagop Kantarjian, Michael J. Keating, Jan A. Burger

Blood (2021) 138 (Supplement 1): 3734.

https://doi.org/10.1182/blood-2021-151711

Published: 2021

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Blood (2021) 138 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2021-154279

Published: 2021

Journal Articles

Assessment of Immunoglobulin Heavy Chain Variable Region ( IGHV ) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD)

Lik Wee Lee, Travers Ching, Bryan Howie, Keyur P. Patel, Philip A. Thompson, Nitin Jain, Alessandra Ferrajoli, Zeev E. Estrov, Jan A. Burger, Michael J. Keating, Rashmi Kanagal-Shamanna, William G. Wierda, Lanny R. Kirsch

Blood (2021) 138 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2021-146611

Published: 2021

Journal Articles

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Hua-Jay J. Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, Jan A. Burger, Philip A. Thompson, Alessandra Ferrajoli, Zeev E. Estrov, Koji Sasaki, Deepa Sampath, Guilin Tang, Xuemei Wang, Hagop Kantarjian, Michael J. Keating, William G. Wierda, Nitin Jain

Blood (2021) 138 (Supplement 1): 394.

https://doi.org/10.1182/blood-2021-146432

Published: 2021

Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-141716

Published: 2020

Journal Articles

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Mariela Sivina, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Philip A. Thompson, MB, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141014

Published: 2020

Journal Articles

Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib

Jade Jones, MD, Binsah Susan George, MD, Christine B Peterson, Thao-Mi Tran Ha, Jan A. Burger, MD PhD, Nitin Jain, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Jean-Bernard Durand, MD, Alessandra Ferrajoli, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-141284

Published: 2020

Journal Articles

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Hua-Jay J Cherng, MD, Nadya Jammal, PharmD, Shilpa Paul, PharmD, Xuemei Wang, MS, Koji Sasaki, MD, Philip A. Thompson, MB, MS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Nitin Jain, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135938

Published: 2020

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-142014

Published: 2020

NARROW

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Assessment of Immunoglobulin Heavy Chain Variable Region ( IGHV ) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD)

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only